Results 181 to 190 of about 1,057,375 (305)

Implementing a "Naloxone Hub With Many Spokes" Model in Kentucky: Partner Agency Perspectives on Implementation Strategies. [PDF]

Implement Res Pract
Knudsen HK, Goetz M, Andrews-Higgins S, Back-Haddix S, Davis OA, Freeman PR, Oyler DR, Walsh SL.   +7 more
europepmc   +1 more source

Implementation strategy

The implementation strategy describes, how a process of change can be geared into a specific historical and political situation and the obstacles and opportunities it offers.
openaire   +1 more source

Directed evolution of enzymes at the crossroads of tradition and innovation

FEBS Open Bio, EarlyView.
An iterative cycle of data‐driven enzyme optimization comprising four stages: genetic diversification of a template enzyme, expression of protein variants, high‐throughput evaluation, and machine‐learning‐guided redesign of the next variant library.
Maria Tomkova, Andrej Mirossay, Erik Sedlak   +2 more
wiley   +1 more source

Correction: Mathematical modeling to assess health and economic impact of cardiovascular interventions and implementation strategies among people living with HIV: SAIA HTN. [PDF]

Implement Sci Commun
Malhotra A, Mocumbi AO, Coutinho MJ, Chidácua MJF, Charama A, Uetela OA, Hazim C, Ramiro I, Sherr K, Gimbel S, Watkins D.   +10 more
europepmc   +1 more source

Hyperosmotic stress‐induced redistribution of pre‐mRNA cleavage factor I subunits is associated with shifts in alternative polyadenylation

FEBS Open Bio, EarlyView.
Hyperosmotic stress triggers the relocation of the CFIm complex from the nucleus to the cytoplasm. This shift creates a nuclear ‘stoichiometric bottleneck’, limiting CFIm availability for mRNA processing. Consequently, specific mRNAs like NUDT21 and DICER1 undergo targeted 3′UTR shortening, demonstrating how spatial protein dynamics drive rapid ...
Hitomi Soumiya, Masatake Osawa, Hidefumi Fukumitsu   +2 more
wiley   +1 more source

Global Investigation of Clinical Implementation Strategies for DPYD Testing to Guide Fluoropyrimidine Therapy. [PDF]

Clin Transl Sci
El Rouby N, Aquilante CL, Bargal SA, Cavallari LH, Duarte JD, Gunderson K, Mazhindu T, Nagy M, Nie X, Nguyen DG, Patel JN, Skaar TC, Smith DM, Tuteja S, van Schaik RHN, Hicks JK, PGRN Implementation Working Group.   +16 more
europepmc   +1 more source

MagmaFlow: A desktop platform for artificial intelligence‐driven expression analysis

FEBS Open Bio, EarlyView.
MagmaFlow is a free, no‐code platform for gene expression analysis. It generates interactive volcano plots, links genes to literature, pathways, and diseases, prioritizes candidates using millions of publications, identifies affected biological processes, builds network diagrams, and exports publication‐ready figures and reports for macOS and Windows ...
Carlos E. Buss, Ao Li, Eduardo H. Gilglioni, Mayank Bansal, Sumeet Pal Singh, Latifa Bakiri, Alessandra K. Cardozo, Esteban N. Gurzov   +7 more
wiley   +1 more source

A pragmatic approach to estimating the cost to deliver and participate in implementation strategies. [PDF]

Implement Sci
Cheng H, Abdel Magid M, McGovern MP, Ford JH, Manja V, Chokron Garneau H, Wagner TH.   +6 more
europepmc   +1 more source

Heterotropic regulation and negative homotropic cooperativity

FEBS Open Bio, EarlyView.
We identified a structural module common to some proteins that couple negative cooperativity with heterotropic regulation, two features that rarely coexist. These proteins are ring‐like and present an ordered asymmetry whereby noncontacting subunits are symmetric, and their tertiary structure differs from that of contacting subunits.
Veronica Morea, Francesco Angelucci, Federica Arnesano, Gianmarco Pascarella, Patrizio Di Micco, Andrea Bellelli   +5 more
wiley   +1 more source

Risk Prediction Models for Recurrence After Curative Treatment of Early‐Stage or Locally Advanced Lung Cancer: A Systematic Review

Aging and Cancer, EarlyView.
This systematic review synthesizes prognostic models for survival and recurrence in resected non‐small cell lung cancer. While many models demonstrate moderate to good discrimination, few are externally validated and reporting quality is variable, limiting clinical applicability and highlighting the need for robust, transparent model development ...
Evangeline Samuel, S. Tissera, E. Paul, J. Zalcberg, R. G. Stirling   +4 more
wiley   +1 more source